GABA receptors: Pharmacological potential and pitfalls

Current Pharmaceutical Design

Volumn 21, Issue 34, 2015, Pages 4943-4959

  Jembrek, Maja Jazvinšćak ^a,b   Vlainić, Josipa ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b Croatian Academy of Medical Sciences Zagreb   (Croatia)

Author keywords

Benzodiazepines; GABA; GABA receptor pharmacology; Neurosteroids

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALCOHOL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; NEUROSTEROID; NEUROTRANSMITTER; 4 AMINOBUTYRIC ACID; GABAERGIC RECEPTOR AFFECTING AGENT; LIGAND;

AGGRESSIVENESS; ALLOSTERISM; ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG BINDING SITE; DRUG RECEPTOR BINDING; EPILEPSY; HUMAN; INSOMNIA; LIGAND BINDING; MAMMAL; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPASTICITY; ANIMAL; BINDING SITE; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; BINDING SITES; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; LIGANDS; RECEPTORS, GABA; RECEPTORS, GABA-B; SYNAPTIC TRANSMISSION;

EID: 84947999159     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150914121624     Document Type: Article

References (254)

1. Somogyi P, Klausberger T. Defined types of cortical interneurone structure space and spike timing in the hippocampus. J Physiol 2005; 562(Pt 1): 9-26.
2. Buzsáki G, Kaila K, Raichle M. Inhibition and brain work. Neuron 2007; 56: 771-83.
3. Ferando I, Mody I. Interneuronal GABAA receptors inside and outside of synapses. Curr Opin Neurobiol 2014; 26: 57-63.
4. Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 2011; 10(9): 685-97.
5. Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem 2012; 287(48): 40224-31.
6. Korpi ER, Grunder G, Lüddens H. Drug interactions at GABA(A) receptors. Prog Neurobiol 2002; 67: 113-59.
7. Tsang SY, Xue H. Development of effective therapeutics targeting the GABAA receptor: naturally occurring alternatives. Curr Pharm Des 2004; 10(9): 1035-44.
8. Licata SC, Rowlett JK. Abuse and dependence liability of benzodiazepine- type drugs: GABA(A) receptor modulation and beyond. Pharmacol Biochem Behav 2008; 90(1): 74-89.
9. Vlainić J, Peričić D. Effects of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam. Neuropharmacology 2009; 56(8): 1124-30.
10. Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci 2012: 416864.
11. Jazvinšćak Jembrek M, Vlainić J, Šuran J. Zolpidem withdrawal induced uncoupling of GABAA receptors in vitro associated with altered GABAA receptor subunit mRNA expression. Acta Neurobiol Exp 2015; 75: 160-71.
12. Bowery NG, Bettler B, Froestl W, et al. International Union of Pharmacology. XXXIII. Mammalian γ-aminobutyric acid (B) receptors: structure and function. Pharmacol Rev 2002; 54(2): 247- 64.
13. Miller PS, Smart TG. Binding, activation and modulation of Cysloop receptors. Trends Pharmacol Sci 2010; 31(4): 161-74.
14. Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid (A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update Pharmacol Rev 2008; 60(3): 243-60.
15. Barnard EA, Skolnick P, Olsen RW, et al. International union of pharmacology: XV. Subtypes of p-Aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 2008; 50: 291-313.
16. Sieghart W, Fuchs K, Tretter V, et al. Structure and subunit composition of GABA receptors. Neurochem Int 1999; 34: 379-85.
17. Uusi-Oukari M, Korpi ER. Regulation of GABAA receptor subunit expression by pharmacological agents. Pharmacol Rev 2010; 62(1): 97-135.
18. Hörtnagl H, Tasan RO, Wieselthaler A, Kirchmair E, Sieghart W, Sperk G. Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Neuroscience 2013; 236: 345- 72.
19. Laurie DJ, Seeburg PH, Wisden W. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. J Neurosci 1992; 12(3): 1063-76.
20. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992; 12(3): 1040- 62.
21. Zhang D, Pan ZH, Awobuluyi M, Lipton SA. Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors. Trends Pharmacol Sci 2001; 22(3): 121-32.
22. Glykys J, Mann EO, Mody I. Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? J Neurosci 2008; 28(6): 1421-6.
23. Fritschy JM, Panzanelli P. GABAA receptors and plasticity of inhibitory neurotransmission in the central nervous system. Eur J Neurosci 2014; 39(11): 1845-65
24. Olsen RW, Sieghart W. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009; 56: 141-8.
25. Chen ZW, Olsen RW. GABAA receptor associated proteins: a key factor regulating GABAA receptor function. J Neurochem 2007; 100(2): 279-94.
26. Darlison MG, Pahal I, Thode C. Consequences of the evolution of the GABA(A) receptor gene family. Cell Mol Neurobiol 2005; 25(3-4): 607-24.
27. Daniel C, Ohman M. RNA editing and its impact on GABAA receptor function. Biochem Soc Trans 2009; 37(Pt 6): 1399-403.
28. Jin P, Zhang J, Rowe-Teeter C, Yang J, Stuve LL, Fu GK. Cloning and characterization of a GABAA receptor r2 subunit variant. J Biol Chem 2004; 279: 1408-14.
29. Dredge BK, Darnell RB. Nova regulates GABA(A) receptor γ2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer. Mol Cell Biol 2003; 23(13): 4687-700.
30. Tretter V, Ehya N, Fuchs K, Sieghart W. Stoichiometry and assembly of a recombinant GABAA receptor subtype. J Neurosci 1997; 17: 2728-37.
31. Gunn BG, Cunningham L, Mitchell SG, Swinny JD, Lambert JJ, Belelli D. GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response. Front Neuroendocrinol 2015; 36: 28-48.
32. Baumann SW, Baur R, Sigel E. Forced subunit assembly in [11222 GABAA receptors. Insight into the absolute arrengement. J Biol Chem 2002; 277: 46020-5.
33. Pöltl A, Hauer B, Fuchs K, Tretter V, Sieghart W. Subunit composition and quantitative importance of GABA(A) receptor subtypes in the cerebellum of mouse and rat. J Neurochem 2003; 87(6): 1444-55.
34. Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem 2002; 2(8): 795-816.
35. Minier F, Sigel E. Positioning of the [-subunit isoforms confers a functional signature to f-aminobutyric acid type A receptors. Proc Natl Acad Sci USA 2004; 101(20): 7769-74.
36. Zezula J, Slany A, Sieghart W. Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits. Eur J Pharmacol 1996; 301: 207-14.
37. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. Nat Rev Neurosci 2005; 6: 215-29.
38. Belelli D, Harrison NL, Maguire J, Macdonald RL, Walker MC, Cope DW. Extrasynaptic GABAA receptors: form, pharmacology, and function. J Neurosci 2009; 29: 12757-63.
39. Brickley SG, Mody I. Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. Neuron 2012; 73(1): 23-34.
40. Carver CM, Reddy DS. Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology (Berl) 2013; 230(2): 151-88.
41. Whissell PD, Lecker I, Wang DS, Yu J, Orser BA. Altered expression of δGABAA receptors in health and disease. Neuropharmacology 2015; 88: 24-35.
42. Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature 2010; 468(7321): 305-9.
43. Bonin RP, Labrakakis C, Eng DG, Whissell PD, De Koninck Y, Orser BA. Pharmacological enhancement of δ-subunit-containing GABA(A) receptors that generate a tonic inhibitory conductance in spinal neurons attenuates acute nociception in mice. Pain 2011; 152(6): 1317-26.
44. Cushman JD, Moore MD, Olsen RW, Fanselow MS. The role of the δ GABA(A) receptor in ovarian cycle-linked changes in hippocampus- dependent learning and memory. Neurochem Res 2014; 39(6): 1140-6.
45. Maguire JL, Stell BM, Rafizadeh M, Mody I. Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 2005; 8(6): 797-804.
46. Maguire J, Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron 2008; 59(2): 207-13.
47. Maldonado-Avilés JG, Curley AA, et al. Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 2009; 166(4): 450-9.
48. Genud R, Merenlender A, Gispan-Herman I, Maayan R, Weizman A, Yadid G. DHEA lessens depressive-like behavior via GABA-ergic modulation of the mesolimbic system. Neuropsychopharmacology 2009; 34(3): 577-84.
49. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABAA receptor. Nat Rev Neurosci 2005; 6: 565-75.
50. Barbaccia ML, Serra M, Purdy RH, Biggio G. Stress and neuroactive steroids. Int Rev Neurobiol 2001; 46: 243-72.
51. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol 2001; 145(6): 669-679.
52. Morrow AL, Biggio G, Serra M, et al. The role of neuroactive steroids in ethanol/stress interactions: proceedings of symposium VII at the Volterra conference on alcohol and stress. Alcohol 2009; 43(7): 521-30.
53. Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA. Neurosteroid modulation of GABAA receptors. Prog Neurobiol 2003; 71: 67-80.
54. Comenencia-Ortiz E, Moss SJ, Davies PA. Phosphorylation of GABAA receptors influences receptor trafficking and neurosteroid actions. Psychopharmacology (Berl) 2014; 231(17): 3453-65.
55. Sigel E, Baur R, Rácz I, et al. The major central endocannabinoid directly acts at GABA(A) receptors. Proc Natl Acad Sci USA 2011; 108(44): 18150-5.
56. Baur R, Kielar M, Richter L, Ernst M, Ecker GF, Sigel E. Molecular analysis of the site for 2-arachidonylglycerol (2-AG) on the a2 subunit of GABAA receptors. J Neurochem 2013; 126(1): 29-36.
57. Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Rev 1999; 29: 196-217.
58. Ernst M, Bruckner S, Boresch S, Sieghart W. Comparative models of GABAA receptor extracellular and transmembrane domains: important insights in pharmacology and function. Mol Pharmacol 2005; 68(5): 1291-300.
59. Sieghart W. Structure and pharmacology of GABAA receptor subtypes. Pharmacol Rev 1995; 47(2): 181-234.
60. Rho JM, Donevan SD, Rogawski MA. Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. J Physiol 1996; 497: 509-22.
61. Rosen A, Bali M, Horenstein J, Akabas MH. Channel opening by anesthetics and GABA induces similar changes in the GABAA receptor M2 segment. Biophys J 2007; 92(9): 3130-9.
62. Bianchi MT, Botzolakis EJ, Lagrange AH, Macdonald RL. Benzodiazepine modulation of GABA(A) receptor opening frequency depends on activation context: a patch clamp and simulation study. Epilepsy Res 2009; 85(2-3): 212-20.
63. Garcia PS, Kolesky SE, Jenkins A. General anesthetic actions on GABA(A) receptors. Curr Neuropharmacol 2010; 8(1): 2-9.
64. Wagner DA, Czajkowski C. Structure and dynamics of the GABA binding pocket: a narrowing cleft that constricts during activation. J Neurosci 2001; 21: 67-74.
65. Berezhnoy D, Baur R, Gonthier A, Foucaud B, Goeldner M, Sigel E. Conformational changes at benzodiazepine binding sites of GABAA receptors detected with a novel technique. J Neurochem 2005; 92: 859-66.
66. Sieghart W. Allosteric modulation of GABAA receptors via multiple drug-binding sites. Adv Pharmacol 2015; 72: 53-96.
67. Nikolaus S, Antke C, Beu M, Müller HW. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders - results from in vivo imaging studies. Rev Neurosci 2010; 21(2): 119-39.
68. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010; 71(7): 839- 54.
69. Rudolph U, Möhler H. GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol 2014; 54: 483-507.
70. Zarnowska ED, Keist R, Rudolph U, Pearce RA. GABAA receptor α5 subunits contribute to GABAA, slow synaptic inhibition in mouse hippocampus. J Neurophysiol 2009; 101(3): 1179-91.
71. Babateen O, Jin Z, Bhandage A, et al. Etomidate, propofol and diazepam potentiate GABA-evoked GABAA currents in a cell line derived from human glioblastoma. Eur J Pharmacol 2015; 748: 101-7.
72. Członkowska AI, Sienkiewicz-Jarosz H, Siemiatkowski M, Bidziński A, Płaźnik A. The effects of neurosteroids on rat behavior and 3H-muscimol binding in the brain. Pharmacol Biochem Behav 1999; 63(4): 639-46.
73. Ran R, Gu J, Fu J, et al. The role of the GABA-A receptor of the adjacent intact dorsal root ganglion neurons in rats with neuropathic pain. Acta Neurobiol Exp (Wars) 2014; 74(4): 405-14.
74. Johnston GA. Muscimol as an ionotropic GABA receptor agonist. Neurochem Res 2014; 39(10): 1942-7.
75. Mortensen M, Ebert B, Wafford K, Smart TG. Distinct activities of GABA agonists at synaptic- and extrasynaptic-type GABAA receptors. J Physiol 2010; 588(Pt 8): 1251-68.
76. Chandra D, Halonen LM, Linden AM, Procaccini C, et al. Prototypic GABA(A) receptor agonist muscimol acts preferentially through forebrain high-affinity binding sites. Neuropsychopharmacology 2010; 35(4): 999-1007.
77. 3H]flumazenil binding in the dorsolateral prefrontal cortex in schizophrenia are linked to α4 and γ2S mRNA levels respectively. PLoS One 2013; 8(1): e52724.
78. Lee BY, Ban JY, Seong YH. Chronic stimulation of GABAA receptor with muscimol reduces amyloid wwprotein (25-35)-induced neurotoxicity in cultured rat cortical cells. Neurosci Res 2005; 52(4): 347-56.
79. Willow M, Johnston GA. Enhancement of GABA binding by pentobarbitone. Neurosci Lett 1980; 18(3): 323-7.
80. Viapiano MS, de Novara AM, de Plazas SF. Neurosteroid modulation of GABA binding sites in developing avian central nervous system. Neurochem Int 1998; 32(3): 291-8.
81. 3H]Flunitrazepam binding to recombinant t11222S GABAA receptors stably expressed in HEK 293 cells. Biomed Pharmacother 2001; 55(4): 221-8.
82. 35S]TBPS) binding to GABAA receptors in postmortem human brain. Br J Pharmacol 2007; 150(8): 1066-74.
83. Akk G, Li P, Bracamontes J, Wang M, Steinbach JH. Pharmacology of structural changes at the GABAA receptor transmitter binding site. Br J Pharmacol 2011; 162(4): 840-50.
84. Baur R, Sigel E. On high- and low-affinity agonist sites in GABAA receptors. J Neurochem 2003; 87(2): 325-32.
85. Boileau AJ, Evers AR, Davis AF, Czajkowsky C. Mapping the agonist binding site of the GABAA receptor: Evidence for a r- strand. J Neurosci 1999; 19: 4847-54.
86. Bergmann R, Kongsbak K, Sørensen PL, Sander T, Balle T. A Unified Model of the GABAA Receptor Comprising Agonist and Benzodiazepine Binding Sites. PLoS One 2013; 8(1): e52323.
87. Laha KT, Tran PN. Multiple tyrosine residues at the GABA binding pocket influence surface expression and mediate kinetics of the GABAA receptor. J Neurochem 2013; 124(2): 200-9.
88. Baumann SW, Baur R, Sigel E. Individual properties of the two functional agonist sites in GABA(A) receptors. J Neurosci 2003; 23(35): 11158-66.
89. Karim N, Wellendorph P, Absalom N, et al. Low nanomolar GABA effects at extrasynaptic α4β1/β3δ GABA(A) receptor subtypes indicate a different binding mode for GABA at these receptors. Biochem Pharmacol 2012; 84(4): 549-57.
90. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor G1 subtype. Nat Neurosci 2000; 3(6): 587-92.
91. Crestani F, Löw K, Keist R, Mandelli M-J, Möhler H, Rudolph U. Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol 2001; 59: 442-5.
92. Rudolph U, Crestani F, Möhler H. GABA(A) receptor subtypes: dissecting their pharmacological functions.Trends Pharmacol Sci 2001; 22(4): 188-94.
93. Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 2005; 14(5): 601-18.
94. Crestani F, Keist R, Fritschy JM, et al. Trace fear conditioning involves hippocampal i5 GABA(A) receptors. Proc Natl Acad Sci USA 2002; 99(13): 8980-5.
95. Collinson N, Kuenzi FM, Jarolimek W, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the l5 subunit of the GABAA receptor. J Neurosci 2002; 22(13): 5572-80.
96. Wisden W, Herb A, Wieland H, Keinänen K, Lüddens H, Seeburg PH. Cloning, pharmacological characteristics and expression pattern of the rat GABA receptor r4 subunit. FEBS Lett 1991; 289: 227-30.
97. Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ. Functional characterization of human gammaaminobutyric acidA receptors containing the r4 subunit. Mol Pharmacol 1996; 50: 670-8.
98. Wallner M, Hanchar HJ, Olsen RW. Alcohol selectivity of β3- containing GABAA receptors: evidence for a unique extracellular alcohol/imidazobenzodiazepine Ro15-4513 binding site at the α+β- subunit interface in αβ3δ GABAA receptors. Neurochem Res 2014; 39(6): 1118-26.
99. Hauser CA, Wetzel CH, Berning B, Gerner FM, Rupprecht R. Flunitrazepam has an inverse agonistic effect on recombinant α6β2γ2-GABAA receptors via a flunitrazepam-binding site. J Biol Chem 1997; 272(18): 11723-7.
100. Sigel E, Lüscher BP. A closer look at the high affinity benzodiazepine binding site on GABAA receptors. Curr Top Med Chem 2011; 11(2): 241-6.
101. Pritchett DB, Sontheimer H, Shivers BD, et al. Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature 1989; 338(6216): 582-5.
102. Hanson SM, Czajkowski C. Structural mechanisms underlying benzodiazepine modulation of the GABA(A) receptor. J Neurosci 2008; 28(13): 3490-9.
103. Kucken AM, Wagner DA, Ward PR, Teissére JA, Boileau AJ, Czajkowski C. Identification of benzodiazepine binding site residues in the ii2 subunit of the 22-aminobutyric acidA receptor. Mol Pharmacol 2000; 57: 932-9.
104. Berezhnoy D, Nyfeler Y, Gonthier A, Schwob H, Goeldner M, Sigel E. On the benzodiazepine binding pocket in GABAA receptors. J Biol Chem 2004; 279: 3160-8.
105. Tan KR, Baur R, Charon S, Goeldner M, Sigel E. Relative positioning of diazepam in the benzodiazepine-binding-pocket of GABA receptors. J Neurochem 2009; 111(5): 1264-73.
106. Bentzen BH, Grunnet M. Central and peripheral GABAA receptor regulation of the heart rate depends on the conscious state of the animal. Adv Pharmacol Sci 2011; 578273.
107. Richter L, de Graaf C, Sieghart W, et al. Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands. Nat Chem Biol 2012; 8(5): 455-64.
108. Walters RJ, Hadley SH, Morris KD, Amin J. Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nat Neurosci 2012; 3(12): 1274-81.
109. Stevenson A, Wingrove PB, Whiting PJ, Wafford KA. beta- Carboline gamma-aminobutyric acidA receptor inverse agonists modulate gamma-aminobutyric acid via the loreclezole binding site as well as the benzodiazepine site. Mol Pharmacol 1995; 48(6): 965-9.
110. Baur R, Tan KR, Lüscher BP, Gonthier A, Goeldner M, Sigel E. Covalent modification of GABAA receptor isoforms by a diazepam analogue provides evidence for a novel benzodiazepine binding site that prevents modulation by these drugs. J Neurochem 2008; 106(6): 2353-63.
111. Suzdak PD, Glowa JR, Crawley JN, Schwartz RD, Skolnick P, Paul SM. A selective imidazobenzodiazepine antagonist of ethanol in the rat. Science 1986; 234(4781): 1243-7.
112. 3δ GABAA receptors. Proc Natl Acad Sci USA 2006; 103(22): 8546-51.
113. Ramerstorfer J, Furtmüller R, Sarto-Jackson I, Varagic Z, Sieghart W, Ernst M. The GABAA receptor α+β- interface: a novel target for subtype selective drugs. J Neurosci 2011; 31(3): 870-7.
114. Spurny R, Ramerstorfer J, Price K, et al. Pentameric ligand-gated ion channel ELIC is activated by GABA and modulated by benzodiazepines. Proc Natl Acad Sci USA 2012; 109(44): E3028-34.
115. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005; 18(3): 249-55.
116. Hood SD, Norman A, Hince DA, Melichar JK, Hulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol 2014; 77(2): 285-94.
117. Janhsen K, Roser P, Hoffmann K. The problems of long-term treatment with benzodiazepines and related substances. Dtsch Arztebl Int 2015; 112(1-2): 1-7.
118. Rundfeldt C, Löscher W. The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs 2014; 28(1): 29-43.
119. Peričić D, Jazvinšćak Jembrek M, Švob Štrac D, Lazić J, Rajčan Špoljarić I. Enhancement of benzodiazepine binding sites following chronic treatment with flumazenil. Eur J Pharmacol 2005; 507(1- 3): 7-13.
120. 2S subunits of GABAA receptors. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 177-87.
121. Jazvinšćak Jembrek M, Švob Štrac D, Vlainić J, Peričić D. The role of transcriptional and translational mechanisms in flumazenilinduced up-regulation of recombinant GABAA receptors. Neurosci Res 2008; 61: 234-41.
122. Švob Štrac D, Vlainić J, Jazvinšćak Jembrek M, Peričić D. Differential effects of diazepam treatment and withdrawal on recombinant GABAA receptor expression and functional coupling. Brain Res 2008; 1246: 29-40.
123. 2S subtype of GABAA receptors in vitro. Acta Pharmacol Sin 2012; 33: 1469-76.
124. Vlainić J, Švob Štrac D, Jazvinšćak Jembrek M, Vlainić T, Peričić D. The effects of zolpidem treatment on GABAA receptors in cultured cerebellar granule cells: changes in functional coupling. Life Sci 2012; 90: 889-94.
125. 3H]tbutylbicycloorthobenzoate binding to recombinant b112222S GABAA receptor. Eur J Pharmacol 1998; 360(1): 99-104.
126. Peričić D, Švob D, Jazvinšćak M, Mirković K. Anticonvulsive effect of swim stress in mice. Pharmacol Biochem Behav 2000; 66(4): 879-86.
127. Walsh LA, Li M, Zhao TJ, Chiu TH, Rosenberg HC. Acute pentylenetetrazol injection reduces rat GABAA receptor mRNA levels and GABA stimulation of benzodiazepine binding with no effect on benzodiazepine binding site density. J Pharmacol Exp Ther 1999; 289(3): 1626-33.
128. Kalueff AV. Mapping convulsants' binding to the GABAA receptor chloride ionophore: a proposed model for channel binding sites. Neurochem Int 2007; 50: 61-8.
129. Im WB, Pregenzer JF. Interaction of La3+ with GABAA receptors in rat cerebrocortical membranes as detected with a35SStbutylbicyclophosphorothionate binding. Eur J Pharmacol Mol Pharmacol Sect 1993; 245: 111-7.
130. Lüddens H, Korpi ER. GABA antagonists differentiate between recombinant GABAA/benzodiazepine receptor subtypes. J Neurosci 1995; 15(10): 6957-62.
131. Fodor L, Bíró T, Maksay G. Nanomolar allopregnanolone potentiates rat cerebellar GABAA receptors. Neurosci Lett 2005; 383: 127- 30.
132. Othman NA, Gallacher M, Deeb TZ, Baptista-Hon DT, Perry DC, Hales TG. Influences on blockade by t-butylbicyclo-phosphorothionate of GABAA receptor spontaneous gating, agonist activation and desensitization. J Physiol 2012; 590(Pt 1): 163-78.
133. Im WB, Blakeman DP. Correlation between γ-aminobutyric acidA receptor ligand-induced changes in tbutylbicyclophosphoro b35SSthionate binding and 36ClCCuptake in rat cerebrocortical membranes. Mol Pharmacol 1991; 39: 394-8.
134. 35S]thionate binding depends on γ- aminobutyric acidA receptor α subunit. Mol Pharmacol 1993; 44: 87-92.
135. Gurley D, Amin J, Ross PC, Weiss DS, White G. Point mutations in the M2 region of the α, β, or γ subunit of the GABAA channel that abolish block by picrotoxin. Rec Channels 1995; 3: 13-20.
136. 2 GABAA receptor subtype. Br J Pharmacol 1995; 115(3): 539-45.
137. Behrends JC. Modulation by bicuculline and penicillin of the block by t-butyl-bicyclo-phosphorothionate (TBPS) of GABAA-receptor mediated Clm-current responses in rat striatal neurones. Br J Pharmacol 2000; 129: 402-408.
138. Grasshoff C, Antkowiak B. Effects of isoflurane and enflurane on GABAA and glycine receptors contribute equally to depressant actions on spinal ventral horn neurones in rats. Br J Anaesth 2006; 97(5): 687-94.
139. Li GD, Chiara DC, Cohen JB, Olsen RW. Numerous classes of general anesthetics inhibit etomidate binding to γ-aminobutyric acid type A (GABAA) receptors. J Biol Chem 2010; 285(12): 8615- 20.
140. Jones MV, Harrison NL, Pritchett DB, Hales TG. Modulation of the GABAA receptor by propofol is independent of the γ subunit. J Pharmacol Exp Ther 1995; 274(2): 962-8.
141. Belelli D, Lambert JJ, Peters JA, Wafford K, Whiting PJ. The interaction of the general anesthetic etomidate with the ii- aminobutyric acid type A receptor is influenced by a single amino acid. Proc Natl Acad Sci USA 1997; 94: 11031-6.
142. Jurd R, Arras M, Lambert S, et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor β3 subunit. FASEB J 2003; 17(2): 250-2.
143. Krasowski MD, O'Shea SM, Rick CE, et al. α subunit isoform influences GABA(A) receptor modulation by propofol. Neuropharmacology 1997; 36(7): 941-9.
144. Lam DW, Reynolds JN. Modulatory and direct effects of propofol on recombinant GABAA receptors expressed in xenopus oocytes: influence of α- and γ2-subunits. Brain Res 1998; 784: 179-87.
145. Feng HJ, Macdonald RL. Multiple actions of propofol on αβγ and αβδ GABAA receptors. Mol Pharmacol 2004; 66: 1517-24.
146. O'Shea SM, Williams CA, Jenkins A. Inverse effects on gating and modulation caused by a mutation in the M2-M3 Linker of the GABA(A) receptor δ subunit. Mol Pharmacol 2009; 76: 641-51.
147. Moraga-Cid G, Yevenes GE, Schmalzing G, Peoples RW, Aguayo LG. A Single phenylalanine residue in the main intracellular loop of α1 γ-aminobutyric acid type A and glycine receptors influences their sensitivity to propofol. Anesthesiology 2011; 115(3): 464-73.
148. Krasowski MD, Koltchine VV, Rick CE, Ye Q, Finn SE, Harrison NL. Propofol and other intravenous anesthetics have sites of action on the γ-aminobutyric acid type A receptor distinct from that for isoflurane. Mol Pharmacol 1998; 53(3): 530-8.
149. Krasowski MD, Nishikawa K, Nikolaeva N, Lin A, Harrison NL. Methionine 286 in transmembrane domain 3 of the GABAA receptor β subunit controls a binding cavity for propofol and other alkylphenol general anesthetics. Neuropharmacology 2001; 41: 952-64.
150. Richardson JE, Garcia PS, O'Toole KK, Derry JM, Bell SV, Jenkins A. A conserved tyrosine in the β2 subunit M4 segment is a determinant of γ-aminobutyric acid type A receptor sensitivity to propofol. Anesthesiology 2007; 107(3): 412-8.
151. 2 γ-aminobutyric acidA receptors. J Neurochem 2002; 80: 140-8.
152. Yip GM, Chen ZW, Edge CJ, et al. A propofol binding site on mammalian GABAA receptors identified by photolabeling. Nat Chem Biol 2013; 9(11): 715-20.
153. Li GD, Chiara DC, Sawyer GW, Husain SS, Olsen RW, Cohen JB. Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. J Neurosci 2006; 26(45): 11599-605.
154. 3H]TDBzl-etomidate, a photoreactive etomidate analogue. Biochemistry 2012; 51(4): 836- 47.
155. Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004; 45(9): 1141-9.
156. Longone P, di Michele F, D'Agati E, Romeo E, Pasini A, Rupprecht R. Neurosteroids as neuromodulators in the treatment of anxiety disorders. Front Endocrinol (Lausanne) 2011; 2: 55.
157. Greenfield LJ Jr. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure 2013; 22(8): 589-600.
158. Hevers W, Lüddens H. The diversity of GABAA receptors. Mol Neurobiol 1998; 18: 35-86.
159. Thompson SA, Whiting PJ, Wafford KA. Barbiturate interactions at the human GABAA receptor-dependence on receptor subunit composition. Br J Pharmacol 1996; 117: 521-7.
160. Steinbach JH, Akk G. Modulation of GABAA receptor channel gating by pentobarbital. J Physiol 2001; 537: 715-33.
161. 1(T260Q) GABAA receptors are directly activated but not modulated by pentobarbital. Eur J Pharmacol 1999; 385: 283-6.
162. Smith AJ, Alder L, Silk J, et al. Effect of α subunit on allosteric modulation of ion channel function in stably expressed human recombinant aa-aminobutyric acidA receptors determined using 36Cl ion flux. Mol Pharmacol 2001; 59: 1108-18.
163. Greenfield LJ Jr., Zaman SH, Sutherland ML, et al. Mutation of the GABAA receptor M1 transmembrane proline increases GABA affinity and reduces barbiturate enhancement. Neuropharmacology 2002; 42: 502-21.
164. Carlson BX, Engblom AC, Kristiansen U, Schousboe A, Olsen RW. A single glycine residue at the entrance to the first membranespanning domain of the γ-aminobutyric acid type A receptor β2 subunit affects allosteric sensitivity to GABA and anesthetics. Mol Pharmacol 2000; 57: 474-84.
165. Chiara DC, Jayakar SS, Zhou X, et al. Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human α1β3γ2 γ-aminobutyric acid type A (GABAA) receptor. J Biol Chem 2013; 288(27): 19343-57.
166. Leśkiewicz M, Budziszewska B, Basta-Kaim A, Zajac A, Kaciński M, Lasoń W. Effects of neurosteroids on neuronal survival: molecular basis and clinical perspectives. Acta Neurobiol Exp (Wars) 2006; 66(4): 359-67.
167. Lambert JJ, Cooper MA, Simmons RD, Weir CJ, Belelli D. Neurosteroids: endogenous allosteric modulators of GABA(A) receptors. Psychoneuroendocrinology 2009; 34: S48-S58.
168. Lambert JJ, Belelli D, Harney SC, Peters JA, Frenguelli BG. Modulation of native and recombinant GABA(A) receptors by endogenous and synthetic neuroactive steroids. Brain Res Brain Res Rev 2001; 37(1-3): 68-80.
169. Belelli D, Casula A, Ling A, Lambert JJ. The influence of subunit composition on the interaction of neurosteroids with GABAA receptors. Neuropharmacology 2002; 43: 651-61.
170. Mennerick S, He Y, Jiang X, et al. Selective antagonism of 5.- reduced neurosteroid effects at GABAA receptor. Mol Pharmacol 2004; 65: 1191-7.
171. Herd MB, Belelli D, Lambert JJ. Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol Ther 2007; 116(1): 20-34.
172. Rupprecht R, Holsboer F. Neuroactive steroids in neuropsychopharmacology. Int Rev Neurobiol 2001; 46: 461-77.
173. Xilouri M, Papazafiri P. Anti-apoptotic effects of allopregnanolone on P19 neurons. Eur J Neurosci 2006; 23: 43-54.
174. Borowicz KK, Piskorska B, Banach M, Czuczwar SJ. Neuroprotective actions of neurosteroids. Front Endocrinol (Lausanne) 2011; 2: 50.
175. Wei J, Xiao GM. The neuroprotective effects of progesterone on traumatic brain injury: current status and future prospects. Acta Pharmacol Sin 2013; 34(12): 1485-90.
176. Shu HJ, Eisenman LN, Jinadasa D, Covey DF, Zorumski CF, Mennerick S. Slow actions of neuroactive steroids at GABAA receptors. J Neurosci 2004; 24(30): 6667-75.
177. Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 2006; 444(7118): 486-9.
178. Akk G, Li P, Bracamontes J, Reichert DE, Covey DF, Steinbach JH. Mutations of the GABA-A receptor α1 subunit M1 domain reveal unexpected complexity for modulation by neuroactive steroids. Mol Pharmacol 2008; 74: 614-27.
179. Bracamontes J, McCollum M, Esch C, et al. Occupation of either site for the neurosteroid allopregnanolone potentiates the opening of the GABAA receptor induced from either transmitter binding site. Mol Pharmacol 2011; 80(1): 79-86.
180. Chisari M, Eisenman LN, Covey DF, Mennerick S, Zorumski CF. The sticky issue of neurosteroids and GABA(A) receptors. Trends Neurosci 2010; 33(7): 299-306.
181. Wohlfarth KM, Bianchi MT, Macdonald RL. Enhanced neurosteroid potentiation of ternary GABAA receptors containing the r subunit. J Neurosci 2002; 22: 1541-9.
182. Puia G, Mienville J-M, Matsumoto K, et al. On the putative physiological role of allopregnanolone on GABAA receptor function. Neuropharmacology 2003; 44: 49-55.
183. Akk G, Covey DF, Evers AS, Mennerick S, Zorumski CF, Steinbach JH. Kinetic and structural determinants for GABA-A receptor potentiation by neuroactive steroids. Curr Neuropharmacol 2010; 8: 18-25.
184. Im WB, Pregenzer JF, Thomsen DR. Effects of GABA and various allosteric ligands on TBPS binding to cloned rat GABAA receptor subtype. Br J Pharmacol 1994; 112: 1025-30.
185. Ahboucha S, Desjardins P, Chatauret N, Pomier-Layrargues G, Butterworth RF. Normal coupling of brain benzodiazepine and neurosteroid modulatory sites on the GABA-A receptor complex in human hepatic encephalopathy. Neurochem Int 2003; 43(6): 551-6.
186. Ahboucha S, Coyne L, Hirakawa R, Butterworth RF, Halliwell RF. An interaction between benzodiazepines and neuroactive steroids at GABAA receptors in cultured hippocampal neurons. Neurochem Int 2006; 48: 703-7.
187. Darbandi-Tonkabon R, Hastings WR, Zeng CM, et al. Photoaffinity labeling with a neuroactive steroid analogue. 6-azipregnanolone labels voltage-dependent anion channel-1 in rat brain. J Biol Chem 2003; 278(15): 13196-206.
188. Park-Chung M, Malayev A, Purdy RH, Gibbs TT, Farb DH. Sulfated and unsulfated steroids modulate γ-aminobutyric acidA receptor function through distinct sites. Brain Res 1999; 830: 72-87.
189. 3δ receptors. Br J Pharmacol 2002, 136: 965-74.
190. Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by iisubunit-containing GABAA receptors. Proc Natl Acad Sci USA 2003; 100: 14439-44.
191. Whissell PD, Eng D, Lecker I, Martin LJ, Wang DS, Orser BA. Acutely increasing δ GABA(A) receptor activity impairs memory and inhibits synaptic plasticity in the hippocampus. Front Neural Circuits 2013; 7: 146.
192. Zheleznova N, Sedelnikova A, Weiss DS. α1β2δ, a silent GABAA receptor: recruitment by tracazolate and neurosteroids. Br J Pharmacol 2008; 153(5): 1062-71.
193. Harney SC, Frenguelli BG, Lambert JJ. Phosphorylation influences neurosteroid modulation of synaptic GABAA receptors in rat CA1 and dentate gyrus neurones. Neuropharmacology 2003; 45: 873-83.
194. Korpi ER, Sinkkonen S. GABAA receptor subtypes as targets for neuropsychiatric drug development. Pharmacol Ther 2006; 109: 12-32.
195. Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 2010; 186: 113-37.
196. Reddy DS, Rogawski MA. Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model. Epilepsy Res 2010; 89(2-3): 254-260.
197. Broomall E, Natale JE, Grimason M, et al. Pediatric superrefractory status epilepticus treated with allopregnanolone. Ann Neurol 2014; 76(6): 911-5.
198. Borghese CM, Stórustovu Sí, Ebert B, et al. The δ subunit of γ- aminobutyric acid type A receptors does not confer sensitivity to low concentrations of ethanol. J Pharmacol Exp Ther 2006; 316(3): 1360-8.
199. 3δ γ-aminobutyric acid type A receptors at low concentrations known to affect humans. Proc Natl Acad Sci USA 2003; 100: 15218-23.
200. Baur R, Kaur KH, Sigel E. Structure of α6β3γ GABA(A) receptors and their lack of ethanol sensitivity. J Neurochem 2009; 111(5): 1172-81.
201. Marutha Ravindran CR, Mehta AK, Ticku MK. Effect of chronic administration of ethanol on the regulation of the a-subunit of GABA(A) receptors in the rat brain. Brain Res 2007; 1174: 47-52.
202. Jin Z, Bazov I, Kononenko O, Korpi ER, Bakalkin G, Birnir B. Selective Changes of GABA(A) Channel Subunit mRNAs in the Hippocampus and Orbitofrontal Cortex but not in Prefrontal Cortex of Human Alcoholics. Front Cell Neurosci 2012; 5: 30.
203. Lindemeyer AK, Liang J, Marty VN, et al. Ethanol-induced plasticity of GABAA receptors in the basolateral amygdala. Neurochem Res 2014; 39(6): 1162-1170.
204. Oršolić N, Benković V, Lisičić D, Ðikić D, Erhardt J, Horvat- Knežević A. Protective effects of propolis and related polyphenolic/ flavonoid compounds against toxicity induced by irinotecan. Med Oncol 2010; 27: 1346-58.
205. Oršolić N, Sirovina D, Gajski G, Garaj-Vrhovac V, Jazvinšćak Jembrek M, Kosalec I. Assessment of DNA damage and lipid peroxidation in diabetic mice: effects of propolis and epigallocatechin gallate (EGCG). Mutat Res 2013; 757(1): 36-44.
206. Jazvinšćak Jembrek M, Vuković L, Puhović J, Erhardt J, Oršolić N. Neuroprotective effect of quercetin against hydrogen peroxideinduced oxidative injury in P19 neurons. J Mol Neurosci 2012; 47: 286-299.
207. Hui KM, Wang XH, Xue H. Interaction of flavones from the roots of Scutellaria baicalensis with the benzodiazepine site. Planta Med 2000; 66(1): 91-93.
208. Hanrahan JR, Chebib M, Johnston GA. Flavonoid modulation of GABA(A) receptors. Br J Pharmacol 2011; 163(2): 234-45.
209. Wolfman C, Viola H, Marder M, et al. Anxioselective properties of 6,3'-dinitroflavone, a high-affinity benzodiazepine receptor ligand. Eur J Pharmacol 1996; 318(1): 23-30.
210. Hall BJ, Karim N, Chebib M, Johnston GA, Hanrahan JR. Modulation of ionotropic GABA receptors by 6-methoxyflavanone and 6- methoxyflavone. Neurochem Res 2014; 39(6): 1068-78.
211. Medina JH, Viola H, Wolfman C, et al. Neuroactive flavonoids: new ligands for the benzodiazepine receptors. Phytomedicine 1998; 5(3): 235-43.
212. Salgueiro JB, Ardenghi P, Dias M, Ferreira MB, Izquierdo I, Medina JH. Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol Biochem Behav 1997; 58(4): 887-91.
213. Kavvadias D, Sand P, Youdim KA, et al. The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. Br J Pharmacol 2004; 142(5): 811-20.
214. Wang F, Xu Z, Yuen CT, et al. 6,2'-Dihydroxyflavone, a subtypeselective partial inverse agonist of GABAA receptor benzodiazepine site. Neuropharmacology 2007; 53(4): 574-82.
215. Hanrahan JR, Chebib M, Johnston GA. Interactions of flavonoids with ionotropic GABA receptors. Adv Pharmacol 2015; 72: 189- 200.
216. Kim HJ, Lee BH, Choi SH, et al.Differential effects of quercetin glycosides on GABAC receptor channel activity. Arch Pharm Res 2015; 108-14.
217. Lau BK, Karim S, Goodchild AK, Vaughan CW, Drew GM. Menthol enhances phasic and tonic GABAA receptor-mediated currents in midbrain periaqueductal grey neurons. Br J Pharmacol 2014; (1): 2803-13.
218. Chebib M, Johnston GAR. The 'ABC' of GABA receptors: a brief review. Clin Exp Pharmacol Physiol 1999; 26: 937-40.
219. Johnston GAR. Medicinal chemistry and molecular pharmacology of GABAC receptors. Curr Top Med Chem 2000; 2: 903-13.
220. Johnston GAR. GABA(A) receptor channel pharmacology. Curr Pharm Des 2005; 11(15): 1867-85.
221. Zhang D, Pan Z-H, Awobuluyi M, Lipton SA. Structure and function of GABAC receptors: a comparison of native versus recombinant receptors. Trends Pharmacol Sci 2001; 22: 121-32.
222. Ng CK, Kim HL, Gavande N, et al. Medicinal chemistry of ρ GABAC receptors. Future Med Chem 2011; 3(2): 197-209.
223. Cunha C, Monfils MH, Ledoux JE. GABA(C) receptors in the lateral amygdala: a possible novel target for the treatment of fear and anxiety disorders? Front Behav Neurosci 2010; 4: 6.
224. Gavande N, Kim HL, Doddareddy MR, Johnston GA, Chebib M, Hanrahan JR. Design, synthesis, and pharmacological evaluation of fluorescent and biotinylated antagonists of ρ1 GABAC receptors. ACS Med Chem Lett 2013; 4(4): 402-7.
225. Johnston GAR. Advantages of an antagonist: bicuculline and other GABA antagonists. Br J Pharmacol 2013; 169(2): 328-36.
226. Morris KDW, Moorefield CN, Amin J. Differential modulation of the tt-aminobutyric acid type C receptor by neuroactive steroids. Mol Pharmacol 1999; 56: 752-9.
227. Johnston GAR. GABAA receptor pharmacology. Pharmacol Ther 1996; 69: 173-98.
228. Zhang J, Xue F, Chang Y. Structural determinants for antagonist pharmacology that distinguish the rho1 GABAC receptor from GABAA receptors. Mol Pharmacol 2008; 74(4): 941-51.
229. Enz R, Cuting GR. Identification of 70 amino acids important for GABAC receptor ρ1 subunit assembly. Brain Res 1999; 846: 177- 85.
230. Adamian L, Gussin HA, Tseng YY, et al. Structural model of rho1 GABAC receptor based on evolutionary analysis: Testing of predicted protein-protein interactions involved in receptor assembly and function. Protein Sci 2009; 18(11): 2371-83.
231. Estrada-Mondragón A, Reyes-Ruiz JM, Martínez-Torres A, Miledi R. Structure-function study of the fourth transmembrane segment of the GABAρ1 receptor. Proc Natl Acad Sci USA 2010; 107(41): 17780-4.
232. Torres VI, Weiss DS. Identification of a tyrosine in the agonist binding site of the homomeric ρ1 γ-aminobutyric acid (GABA) receptor that, when mutated, produces spontaneous opening. J Biol Chem 2002; 277: 43741-8.
233. Amin J. A single hydrophobic residue confers barbiturate sensitivity to t-aminobutyric acid type C receptor. Mol Pharmacol 1999; 55: 411-23.
234. Alakuijala A, TalviOja K, Pasternack A, Pasternack M. Functional characterization of rat ρ2 subunits expressed in HEK 293 cells. Eur J Neurosci 2005; 21(3): 692-700.
235. Goutman JD, Calvo DJ. Studies on the mechanisms of action of picrotoxin, quercetin and pregnanolone at the GABA ρ1 receptor. Br J Pharmacol 2004; 41(4): 717-27.
236. Wang TL, Hackam AS, Guggino WB, Cutting GR. A single amino acid in γ-aminobutyric acid ρ1 receptors affects competitive and noncompetitive components of picrotoxin inhibition. Proc Natl Acad Sci USA 1995; 92(25): 11751-5.
237. Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev 2004; 84(3): 835-67.
238. Bowery NG, Hudson AL, Price GW. GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 1987; 20(2): 365-83.
239. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adín J. Ion channels and epilepsy. Curr Pharm Des 2005; 11(15): 1975-2003.
240. Cryan JF, Kaupmann K. Don't worry 'B' happy!: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci 2005; 26: 36-43.
241. Bettler B, Tiao JY-H. Molecular diversity, trafficking and subcelullar localization of GABAB receptors. Pharmacol Ther 2006; 110: 533-43.
242. Kulik A, Vida I, Luján R, Haas CA, López-Bendito G, Shigemoto R, Frotscher M. Subcellular localization of metabotropic GABA(B) receptor subunits GABA(B1a/b) and GABA(B2) in the rat hippocampus. J Neurosci 2003; 23(35): 11026-35.
243. Tao W, Higgs MH, Spain WJ, Ransom CB. Postsynaptic GABAB receptors enhance extrasynaptic GABAA receptor function in dentate gyrus granule cells. J Neurosci 2013; 33(9): 3738-43.
244. Kaupmann K, Malitschek B, Schuler V, et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 1998; 396(6712): 683-7.
245. Margeta-Mitrovic M, Jan YN, Jan LY. A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron 2000; 27(1): 97-106.
246. Malitschek B, Schweizer C, Keir M, et al. The N-terminal domain of γ-aminobutyric Acid(B) receptors is sufficient to specify agonist and antagonist binding. Mol Pharmacol 1999; 56(2): 448-54.
247. Kniazeff J, Galvez T, Labesse G, Pin JP. No ligand binding in the GB2 subunit of the GABA(B) receptor is required for activation and allosteric interaction between the subunits. J Neurosci 2002; 22(17): 7352-61.
248. Nomura R, Suzuki Y, Kakizuka A, Jingami H. Direct detection of the interaction between recombinant soluble extracellular regions in the heterodimeric metabotropic γ-aminobutyric acid receptor. J Biol Chem 2008; 283(8): 4665-73.
249. Pin J-P, Kniazeff J, Binet V, et al. Activation mechanism of the heterodimeric GABAB receptor. Biochem Pharmacol 2004; 68: 1565-72.
250. Steiger JL, Bandyopadhyay S, Farb DH, Russek SJ. cAMP response element-binding protein, activating transcription factor-4, and upstream stimulatory factor differentially control hippocampal GABABR1a and GABABR1b subunit gene expression through alternative promoters. J Neurosci 2004; 24(27): 6115-26.
251. Galvez T, Duthey B, Kniazeff J, et al. Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J 2001; 20(9): 2152-9.
252. Pin J-P, Kniazeff J, Liu J, Binet V, Goudet C, Rondard P, Prézeau L. Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J 2005; 272: 2947-55.
253. Monnier C, Tu H, Bourrier E, Vol C, et al. Trans-activation between 7TM domains: implication in heterodimeric GABAB receptor activation. EMBO J 2011; 30(1): 32-42.
254. Geng Y, Bush M, Mosyak L, Wang F, Fan QR. Structural mechanism of ligand activation in human GABA(B) receptor. Nature 2013; 504(7479): 254-9.